Cite
Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials.
MLA
Colhoun, Helen M., et al. “Efficacy and Safety of Alirocumab, a Fully Human PCSK9 Monoclonal Antibody, in High Cardiovascular Risk Patients with Poorly Controlled Hypercholesterolemia on Maximally Tolerated Doses of Statins: Rationale and Design of the ODYSSEY COMBO I and II Trials.” BMC Cardiovascular Disorders, vol. 14, Sept. 2014, p. 121. EBSCOhost, https://doi.org/10.1186/1471-2261-14-121.
APA
Colhoun, H. M., Robinson, J. G., Farnier, M., Cariou, B., Blom, D., Kereiakes, D. J., Lorenzato, C., Pordy, R., & Chaudhari, U. (2014). Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovascular Disorders, 14, 121. https://doi.org/10.1186/1471-2261-14-121
Chicago
Colhoun, Helen M, Jennifer G Robinson, Michel Farnier, Bertrand Cariou, Dirk Blom, Dean J Kereiakes, Christelle Lorenzato, Robert Pordy, and Umesh Chaudhari. 2014. “Efficacy and Safety of Alirocumab, a Fully Human PCSK9 Monoclonal Antibody, in High Cardiovascular Risk Patients with Poorly Controlled Hypercholesterolemia on Maximally Tolerated Doses of Statins: Rationale and Design of the ODYSSEY COMBO I and II Trials.” BMC Cardiovascular Disorders 14 (September): 121. doi:10.1186/1471-2261-14-121.